Jeppe Krog Rasmussen is co-founder, CEO and member of the board of DanCann Pharma, a Danish bio-pharma company focusing on research, development, production and sales of medical cannabis and approved drugs containing cannabinoids.

The Company was founded in 2018 by fellow entrepreneurs Jeppe Krog Rasmussen and Morten Martinsen. Jeppe with a business school background and experience in investments, Morten as a relatively newly trained biologist - and both with great interest in the possibilities specified in the Danish Pilot Programme for medical cannabis.

Jeppe Krog Rasmussen comments:

- DanCann Pharma was created with a vision of being able to make a difference - a real alternative - for the many who cannot get adequate help through treatment with conventional medicine. We want to put an end to the stigma that medical cannabis and treatment with cannabinoids has carried for decades.

Jeppe Krog Rasmussen was the youngest ever Danish CEO for a listed company and has since the Company's early start been able to see the value of DanCann Pharma increase significantly. In fact, the Company's Market Cap reached an all-time-high of DKK 175 million at the end of 2021, in less than four years after the establishment.

An IPO in November 2020 and several subsequent capital injections have made it possible for the Company to press the start button in the high-tech production facilities in Biotech Pharm1 and thus start test production of the biomaterial, which in 2022 in larger volumes will be sold in selected export markets. In October 2021, DanCann Pharma acquired the wholesale company CannGros and at the same time acquired import and distribution licenses for the Danish market, which made DanCann Pharma the market leader in Denmark with the only three approved products on the market under the Danish Pilot Programme for medical cannabis.

Further comments from Jeppe Krog Rasmussen:

- The spring of 2022 will be used to obtain the necessary EU-GMP-certifications so that both production and quality systems comply with industry standards. The application for approval of the facilities was sent to the Danish Medicines Agency in January 2022 and we expect to have everything in place during mid-2022.

• Jeppe Krog Rasmussen has a background in a world of investments, with expertise in Tech, MedTech, Biotech and Pharma

• Jeppe Krog Rasmussen has been in charge of all the Company's capital injections, and has historically raised the Company's financing for approx. DKK 90 million

• As a young diabetic, Jeppe Krog Rasmussen was "born" with a curiosity and interest in public health and the well-being of patients. This resulted in the establishment of DanCann Pharma (Danish Cannabinoid Pharmaceuticals), which Jeppe founded at the age of 21

• Jeppe Krog Rasmussen had just moved away from home when DanCann Pharma was listed on the stock exchange in 2020 and - at the age of 25 - historically became the youngest CEO of a Danish IPO ever

• Jeppe Krog Rasmussen was the man behind the Company's first acquisition, CannGros ApS, which the Company acquired for a total of DKK 13 million back in October 2021

• In less than four years, Jeppe Krog Rasmussen has transformed a company founded with a share capital of a few thousand DKK into a forward-thinking listed company, which at the end of 2021 had an "all time high" value of approx. DKK 175 million

• Jeppe Krog Rasmussen is passionate about DanCann Pharma and has committed himself to the Company by locking his commitment for the next three years. A strong signal to current and potential investors

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com